Legal status in Australia. Psilocin is listed as a Schedule 9 (Prohibited Substance) under the Poisons Standard (the document given legislative force by the Therapeutic Goods Act 1989). Psilocybin , its prodrug precursor , shares this classification. Since 1 July 2023, the Therapeutic Goods Administration (TGA) amended the Poisons Standard to permit Authorised Prescribers to access psilocybin (rescheduled to Schedule 8 for that narrow pathway) in the context of treatment-resistant depression. Psilocin itself remains Schedule 9 in all other contexts. Outside an Authorised Prescriber arrangement or a formal TGA Special Access Scheme approval, any possession, use, manufacture, or supply of psilocin or psilocybin is a criminal offence under both Commonwealth and state/territory law. There is no legal avenue for personal or recreational use.
Chemistry and pharmacology. Psilocin (4-hydroxy-N,N-dimethyltryptamine; 4-HO-DMT) is a substituted tryptamine with a molecular formula of C12H16N2O. When psilocybin (the 4-phosphoryloxy analogue found in certain fungi) is ingested, intestinal alkaline phosphatases rapidly dephosphorylate it to yield psilocin. Psilocin crosses the blood–brain barrier and acts primarily as a partial agonist at serotonin 5-HT2A receptors, with additional activity at 5-HT2C and 5-HT1A receptors. This receptor profile is understood to underlie the alterations in perception, cognition, and sense of self reported in clinical and experimental contexts. Psilocin is not considered physiologically addictive by standard pharmacological criteria, but carries meaningful psychological risks, including acute anxiety, paranoia, and psychosis-like episodes , particularly in individuals with personal or family histories of psychotic or bipolar disorders.
Research context. Peer-reviewed studies; including work published in The Lancet Psychiatry and through the Johns Hopkins Center for Psychedelic and Consciousness Research, have examined psilocybin (and by extension psilocin as its active form) in controlled clinical settings. Reported oral doses used in such studies, cited here for descriptive purposes only, have ranged from approximately 10 mg to 30 mg of psilocybin in a supervised environment. These figures appear in the published literature and are not dosing instructions; replicating such conditions outside a lawfully authorised clinical setting is illegal in Australia and carries serious safety risks. The body of current evidence is preliminary, with most trials being small and unblinded, and no psilocybin or psilocin product has been approved by the TGA as a registered therapeutic good for any indication.
Safety and harm profile. The Australian Drug Foundation notes that physiological tolerance to psilocybin/psilocin develops rapidly with repeated use, and cross-tolerance with other serotonergic psychedelics (such as LSD) is documented. Acute adverse effects reported in the literature include tachycardia, hypertension, nausea, and, at higher exposures, intense psychological distress ("difficult experiences" or colloquially "bad trips"). Serotonin syndrome is a documented risk if psilocin is combined with serotonergic medications. Hallucinogen Persisting Perception Disorder (HPPD), whilst rare, is a recognised adverse outcome. Anyone experiencing a psychedelic-related medical emergency should contact emergency services (000 in Australia).
Sources: